DOUGLAS PHARMACEUTICALS LIMITED
Patent Applications and Registrations
Patent applications and USPTO patent grants for DOUGLAS PHARMACEUTICALS LIMITED.The latest application filed is for "compositions comprising lopinavir and treatment of conditions".
- DOUGLAS PHARMACEUTICALS LIMITED - Lincoln, Auckland NZ
- DOUGLAS PHARMACEUTICALS LTD. - Auckland NZ
- DOUGLAS PHARMACEUTICALS LTD - Lincoln, Auckland NZ
- Douglas Pharmaceuticals, Ltd. - NZ NZ
- DOUGLAS PHARMACEUTICALS LIMITED - Henderson Auckland NZ
- Douglas Pharmaceuticals Limited - Auckland NZ
- Douglas Pharmaceuticals Limited - Henderson Auckland NZ
- Douglas Pharmaceuticals Limited - Central Park Drive Lincoln, Auckland NZ
Trademarks
| Patent | Date |
|---|---|
| Compositions Comprising Lopinavir And Treatment Of Conditions App 20220257771 - Hampson; Ian ; et al. | 2022-08-18 |
| Extended Release Pharmaceutical Formulation App 20220183983 - GLUE; Paul William ; et al. | 2022-06-16 |
| Lopinavir And Ritonavir For The Treatment Of Cervix Disorders App 20210213015 - Hampson; Ian ; et al. | 2021-07-15 |
| Treatments App 20210213016 - Hampson; Ian ; et al. | 2021-07-15 |
| Extended release pharmaceutical formulation Grant 11,045,424 - Glue , et al. June 29, 2 | 2021-06-29 |
| Extended Release Pharmaceutical Formulation App 20210052517 - Glue; Paul William ; et al. | 2021-02-25 |
| Extended release pharmaceutical formulation Grant 10,869,838 - Glue , et al. December 22, 2 | 2020-12-22 |
| Extended Release Pharmaceutical Formulation And Methods Of Treatment App 20200306194 - GLUE; Paul William ; et al. | 2020-10-01 |
| Extended release pharmaceutical formulation Grant 10,744,094 - Glue , et al. A | 2020-08-18 |
| Extended Release Pharmaceutical Formulation App 20200000731 - Glue; Paul William ; et al. | 2020-01-02 |
| Extended release pharmaceutical formulation Grant 10,441,544 - Glue , et al. Oc | 2019-10-15 |
| Extended Release Pharmaceutical Formulation App 20190224127 - Glue; Paul William ; et al. | 2019-07-25 |
| Extended Release Pharmaceutical Formulation App 20190216740 - Glue; Paul William ; et al. | 2019-07-18 |
| Extended Release Pharmaceutical Formulation App 20190105276 - Glue; Paul William ; et al. | 2019-04-11 |
| Macrocyclic cysteine protease inhibitors and compositions thereof Grant 9,434,762 - Abell , et al. September 6, 2 | 2016-09-06 |
| Pharmaceutical Methods And Topical Compositions Containing Acitretin App 20140234430 - Surman; Peter ; et al. | 2014-08-21 |
| Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof App 20140194362 - Abell; Andrew David ; et al. | 2014-07-10 |
| Macrocyclic cysteine protease inhibitors and compositions thereof Grant 8,710,178 - Abell , et al. April 29, 2 | 2014-04-29 |
| Pharmaceutical methods and topical compositions containing acitretin App 20130089575 - Surman; Peter ; et al. | 2013-04-11 |
| Stable Suspension Formulation App 20120058993 - Surman; Peter William ; et al. | 2012-03-08 |
| Stable clozapine suspension formulation Grant 8,057,811 - Surman , et al. November 15, 2 | 2011-11-15 |
| Stable clozapine suspension formulation App 20060240050 - Surman; Peter William ; et al. | 2006-10-26 |
| NCAGE Code | EA163 | DOUGLAS PHARMACEUTICALS LTD |
| NCAGE Code | E0292 | DOUGLAS PHARMACEUTICALS LTD |
| CAGE Code | E0292 | DOUGLAS PHARMACEUTICALS LTD |
| CAGE Code | EA163 | DOUGLAS PHARMACEUTICALS LTD |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 